Dienogest mediates midkine suppression in endometriosis
article
OA: bronze
CC0
⤵ 21 in-corpus citations
AI-generated summary
Dienogest treatment suppressed midkine (MK) levels in peritoneal fluid of endometriosis patients and reduced MK mRNA production in isolated endometrial stromal cells.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
STUDY QUESTION: What are the effects of dienogest (DNG) on midkine (MK) production in women with endometriosis? SUMMARY ANSWER: DNG-mediated down-regulation of MK in vivo and in vitro. WHAT IS KNOWN ALREADY: DNG is an oral progestin that alleviates painful symptoms of women with endometriosis with a favourable tolerability and safety profile. Its effects on MK, a growth factor that plays an important role in endometriosis, have not yet been investigated. STUDY DESIGN, SIZE, DURATION: Prospective in vivo study on 283 patients subjected to laparoscopy for benign pathologies in a University hospital and in vitro cultures of primary endometrial stromal cells (ESC) from 6 of these women with histologically confirmed endometriosis. PARTICIPANTS/MATERIALS, SETTING, METHODS: MK concentrations in the peritoneal fluid (PF) of women were measured by ELISA and compared based on endometriosis status and the use of DNG. A subsequent in vitro analysis with ESC was used to confirm the direct influence of DNG and other progestins including, norethisterone acetate (NETA) and medroxyprogesterone acetate (MPA) on MK mRNA production. MAIN RESULTS AND THE ROLE OF CHANCE: The final study population consisted of 253 women. Of these, 165 suffered from endometriosis, with 62 of them taking DNG (DNG group) and 103 taking no hormone treatment (non-DNG group) during at least 3 months before surgery. Another 88 women were endometriosis free (non-endometriosis group). The concentration of MK was highest in the PF of women in the non-DNG group (median 5.26 ng/ml, IQR 2.74-8.46). Significantly lower concentrations were found in the non-endometriosis group (median 3.51 ng/ml, IQR: 1.90-7.53, P = 0.028). The lowest concentrations were found in the DNG group (median 2.44 ng/ml, IQR: 1.12-4.70, P < 0.0001 versus non-DNG group, P = 0.048 versus non-endometriosis group). The treatment of primary cultured ESC with DNG (10(-5) M) suppressed MK mRNA production (P = 0.016), whereas MPA (P = 0.109) and NETA (P = 0.422) at same concentrations did not show a similar effect. LIMITATIONS, REASONS FOR CAUTION: The non-randomized design of the study. WIDER IMPLICATIONS OF THE FINDINGS: These findings could indicate a direct effect of DNG on endometriotic cells that could contribute to its effectiveness in the treatment of this disease. STUDY FUNDING/COMPETING INTERESTS: Funding was received from Swiss National Science Foundation (Grant No. 320030_140774). M.D.M. has received fees for speaking at scientific meetings from Bayer. The other authors have no conflicts of interest to declare.The authors state that the manufacturer of dienogest has in no way influenced the performance or outcomes of this study.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (39)
- Concentrations of Interferon‐γ‐Induced Protein‐10 (IP‐10), an Antiangiogenic Substance, are Decreased in Peritoneal Fluid of Women with Advanced Endometriosis via openalex
- Correlation between symptoms of pain and peritoneal fluid inflammatory cytokine concentrations in endometriosis via openalex
- Dienogest via openalex
- Dienogest inhibits BrdU uptake with G0/G1 arrest in cultured endometriotic stromal cells via openalex
- Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study via openalex
- Does dienogest influence the inflammatory response of endometriotic cells? A systematic review via openalex
- Dysregulation of the Fas/FasL system in mononuclear cells recovered from peritoneal fluid of women with endometriosis via openalex
- EPIDEMIOLOGY OF ENDOMETRIOSIS via openalex
- Estrogen Receptor-β, Estrogen Receptor-α, and Progesterone Resistance in Endometriosis via openalex
- Glucose transporter expression in eutopic endometrial tissue and ectopic endometriotic lesions via openalex
- Immunological aspects of endometriosis: a review. via openalex
- Increased concentrations of soluble tumour necrosis factor receptor (sTNFR) I and II in peritoneal fluid from women with endometriosis via openalex
- Inflammation and nerve fiber interaction in endometriotic pain via openalex
- Interplay between Misplaced Müllerian-Derived Stem Cells and Peritoneal Immune Dysregulation in the Pathogenesis of Endometriosis via openalex
- Kinase signalling pathways in endometriosis: potential targets for non-hormonal therapeutics via openalex
- Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study via openalex
- On-label and off-label drug use in the treatment of endometriosis via openalex
- PAPP-A and osteoprotegerin, together with interleukin-8 and RANTES, are elevated in the peritoneal fluid of women with endometriosis via openalex
- Possible implication of midkine in the development of endometriosis via openalex
- Progesterone and progestational compounds attenuate tumor necrosis factor alpha–induced interleukin-8 production via nuclear factor kappaB inactivation in endometriotic stromal cells via openalex
- Revised American Society for Reproductive Medicine classification of endometriosis: 1996 via openalex
- Stem Cell Factor (SCF) Concentrations in Peritoneal Fluid of Women with or without Endometriosis via openalex
- The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro via openalex
- W2074274229 via openalex
- W2116451502 via openalex
- W1994429470 via openalex
- W2048966093 via openalex
- W1941666251 via openalex
- W2093974096 via openalex
- W2163315477 via openalex
- W2165968193 via openalex
- W2043020964 via openalex
- W1672184366 via openalex
- W2229096149 via openalex
- W2275737843 via openalex
- W2041167474 via openalex
- W2156336275 via openalex
- W2101417341 via openalex
- W2013017387 via openalex
Cited by (22)
- Endometriosis-related peritoneal adhesion formation: molecular mechanisms and clinical significance 2026
- Effects of dienogest treatment on endometrioma-related clinical symptoms and endometrioma size: retrospective cohort study 2025
- Improve the Quality of Life of Women and Reduce Clinical and Morphological Features of Endometriosis under the Influence of Dienogest Preparation 2024
- Additional file 2 of Effects of vitamin D supplementation in endometriosis: a systematic review 2023
- Additional file 1 of Effects of vitamin D supplementation in endometriosis: a systematic review 2023
- Additional file 4 of Effects of vitamin D supplementation in endometriosis: a systematic review 2023
- Additional file 3 of Effects of vitamin D supplementation in endometriosis: a systematic review 2023
- Evaluation of long-term efficacy and safety of dienogest in patients with chronic cyclic pelvic pain associated with endometriosis 2023
- Effects of vitamin D supplementation in endometriosis: a systematic review 2022
- Application of Dienogest In the Treatment of Endometriosis 2022
- The impact of endometriosis and adenomyosis on the female reproductive system 2022
- The issues of endometriosis hormonal treatment in reproductive age women 2022
- The effectiveness of therapy for endometriosis-associated pelvic pain resistant to surgical treatment 2021
- A progestin isn’t a progestin: dienogest for endometriosis as a blueprint for future research – Review as a contribution for discussion - 2020
- Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure 2020
- Peritoneal fluid biomarkers in patients with endometriosis: a cross-sectional study 2020
- The quality of life of women and morphological changes in the glands of adenomyosis under the influence of dienogest-containing preparations 2020
- Endometriosis – a decade later – still an enigmatic disease. What is the new in the diagnosis and treatment? 2019
- Placenta previa and placental abruption after assisted reproductive technology in patients with endometriosis: a systematic review and meta-analysis 2018
- Long-term treatment of endometriosis with dienogest: retrospective analysis of efficacy and safety in clinical practice 2018
- Endometriotic inflammatory microenvironment induced by macrophages can be targeted by niclosamide† 2018
- The possibility of treatment with dienogest 2 mg in patients with genital endometriosis 2017
Source provenance
- europepmc
- last seen: 2026-08-21T06:14:13.963979+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:21:00.404924+00:00
License: CC0
· commercial use OK